MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2

FEBS Open Bio

Volumn 5, Issue , 2015, Pages 893-899

  Shao, Junwei ^a   Cao, Jun ^a   Liu, Yong ^a   Mei, Hongliang ^a   Zhang, Yang ^a   Xu, Weitian ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Apoptosis; Forkhead box F2; Hepatocellular carcinoma; MicroRNA 519a; Proliferation

Indexed keywords

MICRORNA; MICRORNA 519A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXF2; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA CELL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUH7 CARCINOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SMMC 7721 CARCINOMA CELL; TUMOR VOLUME; UPREGULATION;

EID: 84946818996     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2015.10.009     Document Type: Article

References (26)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30. 10.3322/caac.21166.
2. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 10.1016/S0140-6736(11)61347-0.
3. Dhanasekaran R., Limaye A., Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat. Med. 2012, 4:19-37. 10.2147/HMER.S16316.
4. Aravalli R.N., Steer C.J., Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063. 10.1002/hep.22580.
5. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531. 10.1038/nrg1379.
6. Yates L.A., Norbury C.J., Gilbert R.J. The long and short of microRNA. Cell 2013, 153:516-519. 10.1016/j.cell.2013.04.003.
7. Osman A. MicroRNAs in health and disease-basic science and clinical applications. Clin. Lab. 2012, 58:393-402.
8. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 2012, 13:239-250. 10.1038/nrm3313.
9. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866. nrc1997 [pii] 10.1038/nrc1997.
10. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355. 10.1038/nature10888.
11. Yang N., Ekanem N.R., Sakyi C.A., Ray S.D. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv. Drug Deliv. Rev. 2015, 81:62-74. 10.1016/j.addr.2014.10.029.
12. Kim T.H., Kim Y.K., Kwon Y., Heo J.H., Kang H., Kim G., An H.J. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010, 57:734-743. 10.1111/j.1365-2559.2010.03686.x.
13. Ward A., Shukla K., Balwierz A., Soons Z., Konig R., Sahin O., Wiemann S. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J. Pathol. 2014, 233:368-379. 10.1002/path.4363.
14. An F., Zhang Z., Xia M., Xing L. Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways. Oncol. Rep. 2015, 10.3892/or.2015.4150.
15. Cho W.C. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42:1273-1281. 10.1016/j.biocel.2009.12.014.
16. Bruix J., Gores G.J., Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014, 63:844-855. 10.1136/gutjnl-2013-306627.
17. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017. 10.1016/j.cell.2009.04.021.
18. Wang W., Zhao L.J., Tan Y.X., Ren H., Qi Z.T. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012, 33:1113-1120. 10.1093/carcin/bgs113.
19. Wang W., Zhao L.J., Tan Y.X., Ren H., Qi Z.T. Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J. Gastroenterol. 2012, 18:5442-5453. 10.3748/wjg.v18.i38.5442.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013.
21. van den Brink G.R., Rubin D.C. Foxf2: a mesenchymal regulator of intestinal adenoma development. Gastroenterology 2013, 144:873-876. 10.1053/j.gastro.2013.03.016.
22. Cai J., Tian A.X., Wang Q.S., Kong P.Z., Du X., Li X.Q., Feng Y.M. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015, 10.1016/j.canlet.2015.07.001.
23. Wang Q.S., Kong P.Z., Li X.Q., Yang F., Feng Y.M. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer. Breast Cancer Res. 2015, 17:30. 10.1186/s13058-015-0531-1.
24. Kundu S.T., Byers L.A., Peng D.H., Roybal J.D., Diao L., Wang J., Tong P., Creighton C.J., Gibbons D.L. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene 2015, 10.1038/onc.2015.71.
25. Hirata H., Ueno K., Shahryari V., Deng G., Tanaka Y., Tabatabai Z.L., Hinoda Y., Dahiya R. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS ONE 2013, 8:e55502. 10.1371/journal.pone.0055502.
26. Shi Z., Liu J., Yu X., Huang J., Shen S., Zhang Y., Han R., Ge N., Yang Y. Loss of FOXF2 expression predicts poor prognosis in hepatocellular carcinoma patients. Ann. Surg. Oncol. 2015, 10.1245/s10434-015-4515-2.